MBX Biosciences (MBX) Other Accumulated Expenses (2023 - 2026)

MBX Biosciences has disclosed Other Accumulated Expenses across 4 years of filings, most recently posting $294000.0 for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $294000.0, down 93.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $294000.0 (down 93.68% YoY), and the FY2025 annual result was $621000.0, down 79.73% from the prior year.
• Other Accumulated Expenses came in at $294000.0 for Q1 2026 at MBX Biosciences, down from $621000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $4.8 million in Q3 2025 to a low of $211000.0 in Q2 2025.
• The 4-year median for Other Accumulated Expenses is $2.0 million (2023), against an average of $2.3 million.
• Across the five-year window, Other Accumulated Expenses surged 239.2% in 2024 and sank 93.68% in 2026, its largest moves.
• MBX Biosciences' Other Accumulated Expenses stood at $903000.0 in 2023, then soared by 239.2% to $3.1 million in 2024, then sank by 79.73% to $621000.0 in 2025, then tumbled by 52.66% to $294000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $294000.0 (Q1 2026), $621000.0 (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.